Application of disitamab vedotin in the multiline treatment of EGFR mutation-positive lung adenocarcinoma with Her-2 overexpression
ObjectiveTo explore the efficacy of c in the multiline treatment of late-stage lung adenocarcinoma with Her-2 overexpression and epidermal growth factor receptor (EGFR) mutations.MethodsWe summarize the diagnosis and treatment of a female patient with EGFR 21L858R mutation combined with Her-2 overex...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-12-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2024.1472545/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846127348887322624 |
|---|---|
| author | Meiling Lan Tianyun Wang Diexiao Luo Yan Chen Wei Liang Rui Kong Qichao Xie |
| author_facet | Meiling Lan Tianyun Wang Diexiao Luo Yan Chen Wei Liang Rui Kong Qichao Xie |
| author_sort | Meiling Lan |
| collection | DOAJ |
| description | ObjectiveTo explore the efficacy of c in the multiline treatment of late-stage lung adenocarcinoma with Her-2 overexpression and epidermal growth factor receptor (EGFR) mutations.MethodsWe summarize the diagnosis and treatment of a female patient with EGFR 21L858R mutation combined with Her-2 overexpression in advanced lung adenocarcinoma, and analyze the effect of c in her treatment process.ResultsThe patient was diagnosed with lung adenocarcinoma 8 years ago. After first-line treatment, the lung lesions enlarged. Following second-line treatment 5 years ago, intracranial metastasis occurred. After third-line treatment 3 years ago, intracranial and lung lesions enlarged. New lesions in the lungs, liver, and spleen appeared after fourth-line treatment 32 months ago. Lung progression occurred after fifth-line treatment 29 months ago. Liver and lung progression occurred after sixth-line treatment 22 months ago. Lung progression occurred after seventh-line treatment 19 months ago. The patient underwent eighth-line treatment with disitamab vedotin (RC48) + lung radiotherapy + liver intervention 13 months ago. Currently, the patient’s condition is stable, with a good quality of life, and the efficacy assessment is stable disease (SD). Conclusion: Her-2 overexpression can occur in late-stage EGFR-mutant lung adenocarcinoma after multiline treatment. RC48 can achieve sustained remission in these patients. |
| format | Article |
| id | doaj-art-fe7d2cb7f43a4ef7b71ea83ca7689b1b |
| institution | Kabale University |
| issn | 2234-943X |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj-art-fe7d2cb7f43a4ef7b71ea83ca7689b1b2024-12-12T05:10:26ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2024-12-011410.3389/fonc.2024.14725451472545Application of disitamab vedotin in the multiline treatment of EGFR mutation-positive lung adenocarcinoma with Her-2 overexpressionMeiling Lan0Tianyun Wang1Diexiao Luo2Yan Chen3Wei Liang4Rui Kong5Qichao Xie6Department of Oncology, The Third Affiliated Hospital of Chongqing Medical University, Chongqing, ChinaDepartment of Oncology, The Third Affiliated Hospital of Chongqing Medical University, Chongqing, ChinaDepartment of Oncology, The Third Affiliated Hospital of Chongqing Medical University, Chongqing, ChinaDepartment of Pathology, Daping Hospital, Army Medical University, Chongqing, ChinaDepartment of Oncology, The Third Affiliated Hospital of Chongqing Medical University, Chongqing, ChinaDepartment of Oncology, The Third Affiliated Hospital of Chongqing Medical University, Chongqing, ChinaDepartment of Oncology, The Third Affiliated Hospital of Chongqing Medical University, Chongqing, ChinaObjectiveTo explore the efficacy of c in the multiline treatment of late-stage lung adenocarcinoma with Her-2 overexpression and epidermal growth factor receptor (EGFR) mutations.MethodsWe summarize the diagnosis and treatment of a female patient with EGFR 21L858R mutation combined with Her-2 overexpression in advanced lung adenocarcinoma, and analyze the effect of c in her treatment process.ResultsThe patient was diagnosed with lung adenocarcinoma 8 years ago. After first-line treatment, the lung lesions enlarged. Following second-line treatment 5 years ago, intracranial metastasis occurred. After third-line treatment 3 years ago, intracranial and lung lesions enlarged. New lesions in the lungs, liver, and spleen appeared after fourth-line treatment 32 months ago. Lung progression occurred after fifth-line treatment 29 months ago. Liver and lung progression occurred after sixth-line treatment 22 months ago. Lung progression occurred after seventh-line treatment 19 months ago. The patient underwent eighth-line treatment with disitamab vedotin (RC48) + lung radiotherapy + liver intervention 13 months ago. Currently, the patient’s condition is stable, with a good quality of life, and the efficacy assessment is stable disease (SD). Conclusion: Her-2 overexpression can occur in late-stage EGFR-mutant lung adenocarcinoma after multiline treatment. RC48 can achieve sustained remission in these patients.https://www.frontiersin.org/articles/10.3389/fonc.2024.1472545/fullHER-2 overexpressionepidermal growth factor receptorlung adenocarcinomadisitamab vedotinefficacymultiline treatment |
| spellingShingle | Meiling Lan Tianyun Wang Diexiao Luo Yan Chen Wei Liang Rui Kong Qichao Xie Application of disitamab vedotin in the multiline treatment of EGFR mutation-positive lung adenocarcinoma with Her-2 overexpression Frontiers in Oncology HER-2 overexpression epidermal growth factor receptor lung adenocarcinoma disitamab vedotin efficacy multiline treatment |
| title | Application of disitamab vedotin in the multiline treatment of EGFR mutation-positive lung adenocarcinoma with Her-2 overexpression |
| title_full | Application of disitamab vedotin in the multiline treatment of EGFR mutation-positive lung adenocarcinoma with Her-2 overexpression |
| title_fullStr | Application of disitamab vedotin in the multiline treatment of EGFR mutation-positive lung adenocarcinoma with Her-2 overexpression |
| title_full_unstemmed | Application of disitamab vedotin in the multiline treatment of EGFR mutation-positive lung adenocarcinoma with Her-2 overexpression |
| title_short | Application of disitamab vedotin in the multiline treatment of EGFR mutation-positive lung adenocarcinoma with Her-2 overexpression |
| title_sort | application of disitamab vedotin in the multiline treatment of egfr mutation positive lung adenocarcinoma with her 2 overexpression |
| topic | HER-2 overexpression epidermal growth factor receptor lung adenocarcinoma disitamab vedotin efficacy multiline treatment |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2024.1472545/full |
| work_keys_str_mv | AT meilinglan applicationofdisitamabvedotininthemultilinetreatmentofegfrmutationpositivelungadenocarcinomawithher2overexpression AT tianyunwang applicationofdisitamabvedotininthemultilinetreatmentofegfrmutationpositivelungadenocarcinomawithher2overexpression AT diexiaoluo applicationofdisitamabvedotininthemultilinetreatmentofegfrmutationpositivelungadenocarcinomawithher2overexpression AT yanchen applicationofdisitamabvedotininthemultilinetreatmentofegfrmutationpositivelungadenocarcinomawithher2overexpression AT weiliang applicationofdisitamabvedotininthemultilinetreatmentofegfrmutationpositivelungadenocarcinomawithher2overexpression AT ruikong applicationofdisitamabvedotininthemultilinetreatmentofegfrmutationpositivelungadenocarcinomawithher2overexpression AT qichaoxie applicationofdisitamabvedotininthemultilinetreatmentofegfrmutationpositivelungadenocarcinomawithher2overexpression |